SCStephan Chalon

Stephan Chalon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Stephan Chalon has a total of 257 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The pyrrolidinamide antimalarial drug MMV367 rapidly clears blood-stage Plasmodium falciparum in healthy adults with experimental malaria

    by Bridget E. Barber, Robin Denhardt-Eriksson, Etienne A. Guirou, Julia Flynn, Nischal Sahai, Indika Leelasena, Susan Mathison, Chris Moller, Ivan Lim, Carla Evangelista, et al.

    Fast-acting antimalarial drugs are needed to address the emergence of artemisinin resistance in the protozoan parasite Plasmodium falciparum, the major cause of severe malaria worldwide. The pyrrolidinamide antimalarial drug MMV367 (GSK3772701) potentially interferes with parasite metabolism mediated by P. falciparum acyl-CoA synthetases 10 and 11. In this volunteer infection study, the antimalarial activity of MMV367 was tested against blood-stage P. falciparum in 12 healthy malaria-naïve adults. The study participants were inoculated with P. falciparum 3D7–infected erythrocytes on day 0 and received a single oral dose of MMV367 at 3 mg ( n = 3), 5 mg ( n = 2), 10 mg ( n = 1), 20 mg ( n = 3), 90 mg ( n = 2), or 1500 mg ( n = 1) on day 8. All participants received artemether-lumefantrine on or before day 24. Maximum MMV367 plasma concentrations occurred 2 to 4 hours postdose, and the elimination half-life was 12.9 to 18 hours. For doses of ≥20 mg, the parasite clearance half-life was 2.2 to 4.3 hours with viable parasites declining more rapidly (elimination half-life of 1.1 to 2.7 hours). A clearance pharmacokinetic/pharmacodynamic model described the relationship between MMV367 concentrations and parasite killing and subsequent clearance of nonviable parasites. Model-derived efficacy parameters included a minimum inhibitory concentration of 6.3 ng/ml (95% CI, 5.2 to 7.8) and a minimum parasiticidal concentration with 90% of maximum effect of 54 ng/ml (95% CI, 43 to 68). No reduction in in vitro susceptibility to MMV367 or genetic determinants of resistance were observed in drug-exposed parasite lines. Most adverse events were attributed to malaria challenge, and none were serious. Higher MMV367 doses were not associated with an increased incidence or severity of adverse events. These findings support further clinical development of MMV367.

  • Open Access

    Targeting type I regulatory T cells to enhance anti-parasitic T helper 1 and T follicular helper cell responses in human malaria

    by Christian Engwerda, Luzia Bukali, Jessica Engel, Damian Oyong, Fabian de Labastida Rivera, Megan Soon, Dean Andrew, Nicholas Dooley, Mayimuna Nalubega, Reena Mukhiya, et al.

    Type I interferon (IFN) signalling promotes development of type 1 regulatory (Tr1) CD4+ T cells, which suppress inflammation but may limit protective immunity in malaria by constraining effector Th1 cells and antibody-promoting T follicular helper (Tfh) cells. We tested whether transiently blocking IFN-driven JAK/STAT signalling with ruxolitinib would reduce Tr1 cell development and enhance protective Th1 and Tfh cell responses. Using controlled human malaria infection, we investigated the impact of ruxolitinib on CD4+ T cell activation and antigen-specific immunity. Whole blood stimulation with IFNβ, IL-2, or PMA/Ionomycin revealed that ruxolitinib suppressed pSTAT1, pSTAT3, and pSTAT5 in CD4+ T cells following treatment. However, antigen-specific CD4+ T cell responses were preserved. Further, ruxolitinib enhanced recall CD4+ T cell responses during a second infection, with increased frequencies of antigen-specific Th1, Tfh, and Tr1 cell subsets. Transcriptional analysis revealed overlapping gene signatures and clonal sharing between Th1, Tfh and Tr1 cells. These findings show transient JAK inhibition can modulate development of Th1, Tfh and Tr1 cell subsets in malaria, suppressing inhibitory signalling while enhancing the magnitude and durability of the CD4+ T cell recall response following a second infection. Targeting IFN-driven Tr1 cell activity therefore represents a promising host-directed strategy to improve malaria immunity.

  • Open Access

    Nonclinical Considerations for Support of Pregnancy and Lactation in Clinical Trials

    by Dinesh Stanislaus, Christopher J. Bowman, Kimberly C. Brannen, Sarah N. Campion, Laura M. Carlson, Stephan Chalon, Anthony M. DeLise, Claudia Demarta‐Gatsi, Brian P. Enright, Wendy Halpern, et al.

    Background: Pregnant and breastfeeding individuals remain underrepresented in clinical drug development, leaving health care providers and patients with limited data to inform treatment decisions. Current practice relies heavily on nonclinical developmental and reproductive toxicity (DART) studies in animals, while clinical trials typically exclude pregnant and breastfeeding populations or require highly effective contraception for women of childbearing potential. Consequently, medications may be used during pregnancy or lactation despite limited supporting evidence, which can lead to treatment interruption, suboptimal dosing, and increased maternal or fetal risk. Emerging regulatory guidance, including draft ICH Guideline on Inclusion of Pregnant and Breastfeeding Individuals in Clinical Trials (E21), highlights the ethical and clinical need to generate data directly in these populations. Methods: This paper evaluates the current regulatory framework for nonclinical studies described in ICH S5(R3) and M3(R2) and examines how these studies can support the enrollment of pregnant and breastfeeding individuals in clinical trials. It proposes pragmatic adaptations to align nonclinical testing with the anticipated clinical context of use and considers the role of new approach methodologies (NAMs) and alternative study designs. Results: Potential DART strategies are described that could enable the inclusion of pregnant individuals in clinical trials based on factors such as dosing duration, route of administration, and study type (e.g., pharmacokinetic studies). The paper also considers the use of NAMs, including physiologically based pharmacokinetic modeling and in vitro assays, as well as alternative study designs such as preliminary pre‐ and postnatal development or extended embryo–fetal development studies. Approaches to inform studies in breastfeeding populations, including milk–plasma ratio modeling and translation from nonclinical data, are also discussed. Conclusions: These approaches support a shift from routine exclusion toward proactive and ethical inclusion of pregnant and breastfeeding individuals in clinical research, helping address longstanding evidence gaps and improving therapeutic decision‐making.


  • Adjunctive ruxolitinib attenuates inflammation and enhances immunity in volunteers experimentally infected with Plasmodium falciparum

    by Rebecca Webster, Damian A. Oyong, Stacey Llewellyn, Azrin N. Abd-Rahman, Adam J. Potter, Reena Mukhiya, Nischal Sahai, Indika Leelasena, Eniko Ujvary, Sue Mathison, et al.

    Inhibiting the inflammatory response to malaria offers a promising strategy to improve clinical outcomes and overcome immunoregulatory barriers that hinder development of antiparasitic immunity. We conducted a double-blind, randomized, placebo-controlled trial assessing whether ruxolitinib, a Janus-activated kinase (JAK) 1/2 inhibitor, can reduce inflammatory responses and enhance antiparasitic immunity in malaria-naïve volunteers inoculated with blood-stage Plasmodium falciparum . Twenty participants were inoculated and, on day 8, randomized to receive artemether-lumefantrine with either ruxolitinib or placebo. Ninety days later, participants underwent a second inoculation. Ruxolitinib was safe and well tolerated; moreover, it attenuated inflammatory responses to the initial infection, with reduced posttreatment increases in C-reactive protein and markers of disease severity, including angiopoietin-2 and intercellular adhesion molecule-1. Ruxolitinib also enhanced immune memory after the second infection, with elevated human leukocyte antigen–DRA and 4-1BB, consistent with increased T cell activation. These data support the further evaluation of ruxolitinib as an adjunctive treatment to improve clinical outcomes and boost antiparasitic immunity in clinical malaria.


  • Open Access

    Concentration–Response Analysis of the Combination of Pyronaridine and Piperaquine on Corrected QT Interval From a Randomized, Double‐Blind, Placebo‐Controlled Study in Healthy Adults of African Sub‐Saharan Origin

    by Mathieu Felices, Isabelle Borghini‐Fuhrer, Nada Abla, Stephan Chalon

    A novel oral combination of the long‐acting antimalarials pyronaridine (PYR) and piperaquine (PQP) has potential for malaria chemoprevention. This single‐center randomized, double‐blind, placebo‐controlled study assessed the effects of PYR and PQP alone and when co‐administered on Fridericia‐corrected QT interval (QTcF). Between February 14, 2022, and May 31, 2022, thirty‐seven healthy black adults of African sub‐Saharan origin were enrolled and randomized to PYR + PQP ( n = 15), PYR + placebo ( n = 8), PQP + placebo ( n = 8) or double placebo ( n = 6) administered once daily (fasted) for 3 days at doses approved for malaria treatment. Triplicate digitalized electrocardiogram (ECG) recordings and pharmacokinetic samples were taken at matched timepoints. Concentration–response analysis was performed for QTcF changes from baseline (ΔQTcF), and the impact of PYR, PQP, and PYR + PQP administration on placebo‐corrected ΔQTcF (ΔΔQTcF) was assessed. The final qualified and validated concentration–QTc model included a linear component for PYR and an E max component for PQP. The maximum predicted effect on ΔΔQTcF on day 3 was +4.94 msec (90% CI 0.338, 9.54) with PYR + placebo, +19.2 msec (14.6, 23.8) with PQP + placebo, and + 23.1 msec (18.5, 27.6) with PYR + PQP. As expected, PQP increased ΔΔQTcF above the regulatory threshold of concern (+10 msec), whereas PYR did not. The small additional increase in ΔΔQTcF with PYR + PQP coadministration was explained mainly by an increase in PQP C max (1.4‐fold) versus monotherapy. In healthy adults, PYR + PQP coadministration does not appear to increase significantly the effect of PQP on ΔΔQTcF versus PQP administered alone. However, further studies are needed in malaria patients to confirm these findings in the target population. Trial Registration: ClinicalTrials.gov identifier: NCT05160363; EudraCT number: 2021‐005698‐21

  • Open Access

    First‐in‐human safety, tolerability, pharmacokinetics and pilot food‐effect study of the candidate antimalarial compound MMV367

    by Andrea Kuemmerle, Nand Singh, Denis Gossen, Annick Janin, Raman Sharma, Anthony Cahn, Rachel A. Gibson, Somasekhara R. Menakuru, Erin Lambourne, Tom Dove, et al.

    Aim: To evaluate the safety, tolerability and pharmacokinetics in healthy participants of orally administered MMV367 (GSK3772701), a novel antimalarial interfering with Plasmodium falciparum acyl coenzyme A synthetase 10/11 function.Methods: This first‐in‐human study enrolled 47 healthy male and female participants. Part 1 was a randomised, double‐blind, placebo‐controlled study in which four sequential fasted cohorts received MMV367 single ascending doses (100, 300, 750 and 1500 mg) or placebo (six active, two placebo per cohort). Part 2 was a randomised, open‐label crossover (fed‐fasted) pilot food‐effect study of MMV367 440 mg (n = 8). In Part 3 MMV367 400 mg was administered once daily for 3 days in a single cohort (six active, two placebo).Results: Treatment‐emergent adverse events (TEAEs) occurred in 36.8% (14/38) of participants receiving MMV367 vs 44.4% (4/9) with placebo. There were two MMV367‐related TEAEs, and no serious or severe TEAEs or clinically relevant changes in electrocardiograms, vital signs or laboratory tests. In Part 1 (fasted), maximum plasma concentrations occurred between 2.0 and 5.0 h post dose, with a geometric mean half‐life of 16.5‐18.4 h. Approximate dose proportionality was demonstrated across the dose range (100‐1500 mg). In Part 2, MMV367 relative bioavailability (fed vs fasted) was 161.4% (90% confidence interval 148.3, 175.6) for maximum observed concentration (Cmax), 130.4% (122.2, 139.1) for the area under the curve (AUC) until the last measurable concentration and 132.9% (124.1, 142.3) for AUC extrapolated to infinity. In Part 3, geometric mean day 1:3 exposure ratios (geometric co‐efficient of variability) were 1.9 (4.9%) for Cmax and 2.1 (7.7%) for the AUC for the defined interval between doses after once‐daily dosing for 3 days.Conclusions: MMV367 demonstrated acceptable safety, tolerability and pharmacokinetic profiles supporting further development as an antimalarial drug.

  • Open Access

    First‐in‐human safety, tolerability, pharmacokinetics and pilot food‐effect study of the candidate antimalarial compound MMV367

    by Andrea Kuemmerle, Nand Singh, Denis Gossen, Annick Janin, Raman Sharma, Anthony Cahn, Rachel A. Gibson, Somasekhara R. Menakuru, Erin Lambourne, Tom Dove, et al.

    Aim: To evaluate the safety, tolerability and pharmacokinetics in healthy participants of orally administered MMV367 (GSK3772701), a novel antimalarial interfering with Plasmodium falciparum acyl coenzyme A synthetase 10/11 function.Methods: This first‐in‐human study enrolled 47 healthy male and female participants. Part 1 was a randomised, double‐blind, placebo‐controlled study in which four sequential fasted cohorts received MMV367 single ascending doses (100, 300, 750 and 1500 mg) or placebo (six active, two placebo per cohort). Part 2 was a randomised, open‐label crossover (fed‐fasted) pilot food‐effect study of MMV367 440 mg (n = 8). In Part 3 MMV367 400 mg was administered once daily for 3 days in a single cohort (six active, two placebo).Results: Treatment‐emergent adverse events (TEAEs) occurred in 36.8% (14/38) of participants receiving MMV367 vs 44.4% (4/9) with placebo. There were two MMV367‐related TEAEs, and no serious or severe TEAEs or clinically relevant changes in electrocardiograms, vital signs or laboratory tests. In Part 1 (fasted), maximum plasma concentrations occurred between 2.0 and 5.0 h post dose, with a geometric mean half‐life of 16.5‐18.4 h. Approximate dose proportionality was demonstrated across the dose range (100‐1500 mg). In Part 2, MMV367 relative bioavailability (fed vs fasted) was 161.4% (90% confidence interval 148.3, 175.6) for maximum observed concentration (Cmax), 130.4% (122.2, 139.1) for the area under the curve (AUC) until the last measurable concentration and 132.9% (124.1, 142.3) for AUC extrapolated to infinity. In Part 3, geometric mean day 1:3 exposure ratios (geometric co‐efficient of variability) were 1.9 (4.9%) for Cmax and 2.1 (7.7%) for the AUC for the defined interval between doses after once‐daily dosing for 3 days.Conclusions: MMV367 demonstrated acceptable safety, tolerability and pharmacokinetic profiles supporting further development as an antimalarial drug.


  • Open Access

    A randomized, open-label two-period crossover pilot study to evaluate the relative bioavailability in the fed state of atovaquone-proguanil (Atoguanil™) versus atovaquone-proguanil hydrochloride (Malarone®) in healthy adult participants

    by Andrea Kuemmerle, Denis Gossen, Michael W. Marx, Ulrike Lorch, Maja Szramowska, Ashok Kumar, Dharmendra Singh, Satinder Singh, Hanu Ramachandruni, Byju Thankachen, et al.

    Atoguanil™ is a novel complex of atovaquone (ATV) and proguanil (PG) with enhanced ATV bioavailability compared to Malarone®. This pilot study assessed whether the relative bioavailability (Frel) of ATV, PG, and the primary PG metabolite cycloguanil (CG) following a single oral dose in the fed state of Atoguanil was similar to Malarone despite a 50% lower ATV dose. This open-label, single-dose, randomized 2-period, 2-treatment, balanced crossover study was conducted between 17th November 2021 and 18th March 2022. Eligible participants (aged 18–55 years) were randomized (1:1) in period 1 to Atoguanil (ATV/PG 500/348 mg) or Malarone (ATV/PG hydrochloride 1000/400 mg) administered following a high-fat, high caloric meal. After a 24-day washout period, participants crossed treatment arms. For the doses tested, Frel was assumed similar if 90%CIs were between 80 and 125% for the geometric mean ratio of the least square mean differences for each exposure parameter. In 15 evaluable participants, Frel was similar for ATV Cmax (93.6% [90%CI 83.6, 104.9]) but not AUC0-inf (77.8% [67.4, 89.8]), for PG AUC0-inf (95.6% [92.1, 99.2]) but not Cmax (82.4% [75.8, 89.5]), and for both CG Cmax (100.8% [95.0, 107.0]) and AUC0-inf (102.9% [98.4, 107.7]). Nine adverse events occurred; all were of mild severity and not considered treatment related. At the doses tested, ATV Frel was lower following Atoguanil versus Malarone based on AUC0-inf, though when adjusted for dose Frel increased by 156%. Both drugs were well tolerated with no safety concerns. ClinicalTrials.gov: NCT04866602 (April 26th, 2021)


  • Open Access

    Longitudinal changes in iron homeostasis in human experimental and clinical malaria

    by Stephen D. Woolley, Matthew J. Grigg, Louise Marquart, Jeremy S.E. Gower, Kim Piera, Arya Sheela Nair, Fiona M. Amante, Giri S. Rajahram, Timothy William, David M. Frazer, et al.


  • Open Access

    Characterising the blood-stage antimalarial activity of pyronaridine in healthy volunteers experimentally infected with Plasmodium falciparum

    by Bridget E. Barber, Rebecca Webster, Adam J. Potter, Stacey Llewellyn, Nischal Sahai, Indika Leelasena, Susan Mathison, Karsten Kuritz, Julia Flynn, Stephan Chalon, et al.